
#### VALUE ANALYSIS AND INFECTION PREVENTION: CLINICAL PERSPECTIVES OF COLLABORATION

February 2, 2023 Via Webinar



# Disclosures

### None

## **Objectives**

- Discuss the methodology of clinical value analysis in terms of infection prevention and control products.
- Review the steps to objectively evaluate new medical technologies and products.
- Discuss the role of the infection preventionists in the clinical value analysis process

### Disclaimer

 The opinions of the speakers of this program do not represent the official opinions or positions of any specific organization.

#### Karen Niven, MS, BSN, RN, CVAHP Senior Director, Performance Groups Premier, Inc. 2022 AHVAP President-Elect


Karen's primary responsibility is managing the Value Analysis Committee and the clinical process within the Performance Groups line of business. This is an ongoing value analysis process of identifying and articulating market requirements that define a product category's attributes. As a clinical expert she uses her understanding and medical expertise to analyze current and future market technology trends while prioritizing customer needs. In addition, Karen's responsibilities also include assisting the clinical work groups for all Performance Groups as well as working with members and suppliers to identify and develop strategies to introduce new technology and improve product utilization.

Prior to joining Premier, Karen has more than 33 years of nursing experience in the PeriOperative Services area to include circulating, working in PACU and management of all areas in the PeriOperative arena. Her management duties included capital equipment acquisitions, total joint implant management, physician preference product ordering, daily oversight of the Department of Anesthesia, and responsibility for over 50 OR's 12 Endoscopy procedure rooms and all Pre-op and Post-op departments.



## How Do We Define "Value" in Today's Dynamic Healthcare Marketplace?

#### **Defining VBC**





### Relationship of Infection Prevention to Value Analysis



Infection Prevention and Control is a valuable stakeholder to the value analysis process



Must be integrated into the process



Requires understanding of the organization's value analysis goals

### Alignment of Value Analysis to Modern Medicine



### COST QUALITY OUTCOMES



# Where Does Value Analysis Report Into?

This Photo by Unknown Author is licensed under CC BY-SA-NC

### Clinical Integrations

- Integrated HER
- Product Recalls
- Correlations of Product Usage with Clinical Quality and Patient Safety

# Role of National Supply Chain Forces in Value Analysis

## National Influences

- GPOs
- IDNs
- Supply Chain Disruptions/Product Continuity
- New Methods to Conduct Product Training and Competency

How Do We Win Together?




#### **Evidence-Based Product Evaluation**

Evidence-Based Outcomes Patient and Staff Safety Current Organization and Industry-Leading Practices

Regulatory Requirements Total Cost of Care and other Financial Influences

### How Do We Evaluate Evidence?



Source: Kent State University

What is Really Valuable to Value Analysis?

•RCTs? **Other Peer-Reviewed Studies?** Industry-Generated Whitepapers? •Marketing Slicks?

# Building Strong Alliances with Value Analysis Leaders

# Which Do You Want to Be?

#### Non-Integrated

- Transactional
- Not Integrated into Value Analysis Process
- Limited Understanding of Value Analysis Process
- Consulted as Needed

#### **Strategic Partner**

- Strategic-Mindset
- Deeply Integrated into Value Analysis Process
- Seen as true "Partner"
- Proactive Solutions-Drive Partner
- Seat at the Table

# Partnering with Value Analysis Leaders

• • • • • •

•••




Be a Resource to your Value Analysis Team by providing tools, templates, cost-calculators, and clinical evidence



Know the challenges of your health system



Bring a solutions-oriented approach to problem solving




# Become a Trusted Partner: Stand Out from the Crowd

### Our Expectations of You as Infection Preventionists





# The Market is Shifting





#### IMPROVING **POPULATION HEALTH**

Preventing and managing prevalent, costly, and chronic diseases2,4

#### **REDUCING COST OF CARE**

Reducing resource utilization and readmissions while assuming greater risk<sup>2</sup>

#### AIM<sup>3</sup>

#### **OUADRUPLE**


#### **IMPROVING PROVIDER** SATISFACTION

Providing access to tools and resources to address provider burden and burnout<sup>3</sup>

#### **ENHANCING THE** PATIENT EXPERIENCE

Motivating and engaging patients to play an active role in their care to improve outcomes and safety<sup>4</sup>

### Resources



# **Get Involved-Become Certified**







# Thank you-Questions